It's difficult to say what the burn rate would be right now, but...

It's difficult to say what the burn rate would be right now, but i'm expecting it to be around 10-15 mill for the last quarter. If at the lower end then PAR can hold out for another 6 months, but if at the upper end then they might have to think about a CR. A rights issue may be able to cover any potential shortfall in funding requirements for 002, but it is not likely to cover the funding shortfall for 003 or for commercialisation of Zilosul, which they will probably have to tap instos for. It's common for biotech firms to let their coffers rundown, but they first need to make sure they have enough funds for the current programs, which does not include 003 yet since it is not yet active until mid 2023.

In saying that, PAR is expected to announce soon the next steps for advancing the R&D pipeline (MPS, Heart, Alphavirus and Respiratory) using iPPS which might require additional funds depending on what they're planning.